Send me real-time posts from this site at my email
Zacks

Kimberly-Clark (KMB) Queued for Q1 Earnings: Factors to Note

Kimberly-Clark Corporation KMB is likely to witness year-over-year top and bottom-line declines, when it reports first-quarter 2021 numbers on Apr 23. The Zacks Consensus Estimate for revenues is pegged at $4,941 million, which suggests a drop of 1.4% from the figure reported in the prior-year quarter.

The Zacks Consensus Estimate for the bottom line has declined 2% in the past 30 days to $1.92 per share, which indicates a decrease of 9.9% from the year-ago quarter’s reported figure. Notably, the bottom line outperformed the Zacks Consensus Estimate by almost 5% in the last reported quarter, and the company has a trailing four-quarter earnings surprise of 7.4%, on average.

KimberlyClark Corporation Price, Consensus and EPS Surprise

KimberlyClark Corporation price-consensus-eps-surprise-chart | KimberlyClark Corporation Quote

Key Factors to Note

Kimberly-Clark’s K-C Professional segment sales have been declining year over year for a while now due to hurdles related to coronavirus. In fourth-quarter 2020, sales in the segment fell 9% to $742 million, with volumes bearing the brunt of reduced away-from-home demand and tough business conditions after the pandemic.

Apart from these, the company has been encountering high manufacturing costs, including coronavirus-related expenses, for the past few quarters. Also, increased advertising expenses and general and administrative costs have been weighing on profits. In the fourth quarter of 2020, adjusted operating profit came in at $767 million, down from $826 million in the year-ago quarter, thanks to a rise in input costs (to the tune of $40 million) as well as other manufacturing costs, including coronavirus-related expenses.

On its fourth-quarter earnings call, management said that it expects a more difficult environment in 2021, wherein it projects commodity cost inflation of $450-$600 million. The company expects cost increases in most areas, such as resins, pulp and recycled fiber, superabsorbent, and distribution expenses. These factors raise concerns over the quarter under review. That being said, the company’s commitment to reduce costs through its 2018 Global Restructuring Program and the Focus on Reducing Costs Everywhere or the FORCE Program is noteworthy. Additionally, a focus on the three key strategic growth pillars bodes well. These include improving its core business in the developed markets, speeding up growth in the Personal Care segment in developing and emerging markets and enhancing digital and e-commerce capacities.

Moreover, Kimberly-Clark’s Consumer Tissue unit has been doing well, thanks to higher demand stemming from greater work-from-home trends amid the pandemic. Also, the company’s solid innovation and contribution from buyouts are worth noting. Incidentally, Kimberly-Clark’s fourth-quarter sales received a 2% contribution from the Softex Indonesia buyout, which was concluded in October 2020. Sales in the Personal Care segment were aided by 3% from Softex Indonesia.

What the Zacks Model Unveils

Our proven model predicts an earnings beat for Kimberly-Clark this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Kimberly-Clark currently has a Zacks Rank #3 and an Earnings ESP of +0.13%.

Other Stocks With Favorable Combinations

Here are some other companies you may want to consider, as our model shows that these too have the right combination of elements to post an earnings beat this season.

Medifast MED has an Earnings ESP of +6.25% and a Zacks Rank #3, currently. You can see the complete list of today’s Zacks #1 Rank stocks here.

Coty COTY has an Earnings ESP of +16.67% and a Zacks Rank #3, at present.

Boston Beer SAM currently has an Earnings ESP of +17.87% and a Zacks Rank #3.

Zacks Top 10 Stocks for 2021

In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?

Last year's 2020 Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.

Access Zacks Top 10 Stocks for 2021 today >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
KimberlyClark Corporation (KMB): Free Stock Analysis Report
 
The Boston Beer Company, Inc. (SAM): Free Stock Analysis Report
 
MEDIFAST INC (MED): Free Stock Analysis Report
 
Coty Inc. (COTY): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue